Adalimumab for the treatment of rheumatoid arthritis

  title={Adalimumab for the treatment of rheumatoid arthritis},
  author={Nobuyuki Miyasaka},
  journal={Expert Review of Clinical Immunology},
  pages={19 - 26}
  • N. Miyasaka
  • Published 2009
  • Medicine
  • Expert Review of Clinical Immunology
Rheumatoid arthritis (RA) is characterized by massive synovial proliferation resulting in joint destruction and deterioration in quality of life. TNF-α has been implicated in the central pathogenesis of RA, and its blockade? by anti-TNF-α monoclonal antibodies (infliximab and adalimumab) and the soluble TNF-α receptor (etanercept) has caused a paradigm shift in the treatment of RA. Adalimumab can be used alone or concomitantly with methotrexate, but the combination of both is significantly… Expand
Adalimumab in the treatment of arthritis
  • P. Mease
  • Medicine
  • Therapeutics and clinical risk management
  • 2007
Overall, across these indications, adalimumab demonstrated a rapid onset of action, sustained efficacy with long-term treatment, and was well-tolerated, with few patients discontinuing treatment because of adverse events. Expand
Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.
It was found that blocking metabolism at the methyl group of the amine and constructing the tetrahydropyrimidine core were important to obtaining compounds with good biological profiles and oral bioavailability and Pursuing the structure-activity relationships of this series led to the discovery of AS1940477 (3f), with excellent cellular activity and a favorable pharmacokinetic profile. Expand
Discovery and Characterization of Atropisomer PH‐797804, a p38 MAP Kinase Inhibitor, as a Clinical Drug Candidate
Extensive pharmacological characterization supports that PH‐797804 carries most activity both in’vitro and in vivo, and it has a stability profile compatible with oral formulation and delivery options. Expand


Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
In typical clinical practice, adalimumab was effective and well-tolerated in patients with RA previously treated with etanercept and/or infliximab. Expand
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Considering the limitations of an open-label study, adalimumab alone or in combination with standard DMARDs appeared to be well tolerated and effective in 6610 difficult-to-treat patients with active RA treated in clinical practice. Expand
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
In this 52-week trial, adalimumab was more effective than placebo at inhibiting the progression of structural joint damage, reducing the signs and symptoms, and improving physical function in patients with active RA who had demonstrated an incomplete response to MTX. Expand
Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
Patients who received abatacept more often had improved physical function, more frequently met standard response criteria, and less often had radiographic progression of joint damage, as well as serious infections and infusion reactions more often. Expand
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo. Expand
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
Adalimumab given as monotreatment to patients with longstanding, severe RA refractory to traditional DMARDs produced a rapid, sustained response and was safe and well tolerated, with no dose limiting side effects. Expand
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
The data indicate that adalimumab is a safe and effective therapeutic option in patients with active RA who have an inadequate response to standard antirheumatic therapy, including one or more traditional DMARD, corticosteroids, NSAID, and analgesics. Expand
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Serum antibodies against adalimumab are associated with lower serum adalicumab concentrations and non-response to adal optimumab treatment. Expand
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Treatment with MRA was generally well tolerated and significantly reduced the disease activity of RA, and the adverse events were not dose dependent. Expand
Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab in combination with methotrexate after 24 weeks of treatment could induce disease remission in 30% of patients with rheumatoid arthritis refractory to anti-TNF antagonist therapy. Expand